TJ003234

DRUG2 trials

Sponsors

I-Mab Biopharma US Limited

Conditions

Coronavirus Disease 2019 COVID-19Healthy Adult Subjects

Phase 1

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

CompletedNCT03794180

I-Mab Biopharma US LimitedHealthy Adult Subjects

Start: 2019-03-18End: 2019-09-05Updated: 2019-12-18

Phase 2

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

CompletedNCT04341116

I-Mab Biopharma US LimitedCoronavirus Disease 2019 COVID-19

Start: 2020-04-11End: 2022-02-07Updated: 2023-05-06